Treatment effectiveness and safety

We aim to understand disease progression and prognosis for people living with musculoskeletal disease.

We do this by exploring:

• biologic, biosimilar and new targeted therapies;
• conventional synthetic anti-rheumatic drugs and glucocorticoids;
• analgesics for chronic musculoskeletal pain; non-pharmacological treatments.

Academic leads

• Professor Kimme Hyrich
• Professor Terence O’Neill
• Dr Meghna Jani